CA
NZ
UK
AU
IND
US
NEXGEL, Inc. has long been a specialist manufacturer with a narrow story: it makes electron-beam, cross-linked hydrogels in Langhorne, Pennsylvania, sells them to other companies, and layers a few consumer brands on top. Full-year 2025 revenue was $11.4 million. In April 2026 it licensed …
Presbyopia is the least glamorous large market in ophthalmology. Almost everyone develops it, almost nobody treats it with a prescription, and the incumbent remedy costs a few dollars at a pharmacy checkout. LENZ Therapeutics, Inc. (NASDAQ:LENZ) is trying to turn that self-managed condition into …
Medical device stories rarely turn on one regulatory decision, but IceCure Medical Ltd. is close to an exception. On October 3, 2025 the U.S. Food and Drug Administration granted marketing authorization to its De Novo application for the ProSense cryoablation system, making it the …
FibroBiologics, Inc. (NASDAQ:FBLG) is a Houston-based clinical-stage company built on one unfashionable idea: that fibroblasts, the connective-tissue cells usually treated as scaffolding, can be turned into therapies. On June 3, 2026 it announced that the first patients had been enrolled and dosed in a …
On April 29, 2026, enVVeno Medical Corporation (NASDAQ:NVNO) announced that the FDA had awarded it what the company describes as the first-ever investigational device exemption permitting a U.S. pivotal study of a non-surgical replacement venous valve. The trial, named TAVVE, will test the enVVe …
Atossa Therapeutics, Inc. has spent a decade developing one molecule: oral (Z)-endoxifen, the most active metabolite of tamoxifen. On July 21, 2026 the Seattle company announced a poster presented three days earlier at an American Association for Cancer Research conference on rare cancers, setting …
For more than a decade the case for Anavex Life Sciences Corp. rested on one proposition: that blarcamesine, an oral small molecule targeting the sigma-1 receptor, could slow early Alzheimer's disease without the infusions and MRI monitoring that antibody therapies require. Between November 2025 …
Forte Biosciences, Inc. (NASDAQ:FBRX) shares jumped sharply in pre-market trading after argenx (Euronext & Nasdaq:ARGX) announced a definitive agreement to acquire the company for $77.00 per share in cash, representing a total equity value of approximately $2.2 billion. The offer reflects a premium of …
The biotech and pharmaceutical sector entered the final stretch of July with a dense week of regulatory decisions, capital deployment, and clinical data readouts. The aggregate picture reflects a sector navigating the simultaneous pressure of pipeline validation, strategic consolidation, and competitive repositioning in high-value …
Businesses tied to Robert F Kennedy Jr's Make America Healthy Again movement are poised to benefit from a regulatory overhaul in Washington, with companies aligned with his agenda emerging as its earliest winners. At a two-day meeting at the US Food and Drug Administration, …
Please wait processing your request...